Benitec Biopharma IncBNTC
Price$9.58

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$45.5MTTM through 31 Mar 2026
Free Cash Flow -$16.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

-29.6%ROE
-26.1%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio56.82x
Net Debt-$184.8Mnet cash position
Cash & Equivalents$180M

Quality Metrics

Altman Z-Score38.99
Piotroski F-Score2 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24
FY2024: $0
Diluted EPS-$0.93TTM
'21'22'23'24'25'26
FY2026: $-0.98

Dividend

$0.77Per share, FY20180.00%Yield

Capital Allocation

R&D Spend$18.4M

Segment Performance

SegmentRevenueYoYOutlook
Gene Therapy ddRNAi Platform$00.0%
View details

The company is focused on advancing BB-301 through its clinical milestones and plans to meet with the FDA to formalize the pivotal study design.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.